-+ 0.00%
-+ 0.00%
-+ 0.00%

ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial

Dow Jones·10/06/2026 12:52:00

Please log in to view news